Thea Marie Drachen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thea Marie Drachen has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ole Ellegaard
Department of Information Resources, Library, University of Southern Denmark, Odense, Denmark
3 shared publications - Søren Bertil Fabricius Dorch
University of Southern Denmark
3 shared publications - Charlotte Wien
Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
2 shared publications - Najmeh Shaghaei
University of Southern Denmark
2 shared publications - Ane Gjerland
Section Evidence-Based Practice, Department for Health and Function, Western Norway University of Applied Sciences, Bergen, Norway
1 shared publication - Anita L. Thiesen
University of Southern Denmark
1 shared publication
Latest Publications
- Open Access
- 26 March 2024
- Published by Frontiers Media SA in Frontiers in Research Metrics and Analytics
- Vol. 9, 1400009
Editorial: Quality and quantity in research assessment: examining the merits of metrics, volume II
Editorial: Quality and quantity in research assessment: examining the merits of metrics, volume II
- 26 March 2024
- Published by Frontiers Media SA in Frontiers in Research Metrics and Analytics
- Vol. 9, 1400009
Open AccessEditorial: Quality and quantity in research assessment: examining the merits of metrics, volume II
Editorial: Quality and quantity in research assessment: examining the merits of metrics, volume II
- Open Access
- 15 November 2022
- Published by Springer Nature in Systematic Reviews
- Vol. 11 (1) , 1-15
Meta-research evaluating redundancy and use of systematic reviews when planning new studies in health research: a scoping review
Background: Several studies have documented the production of wasteful research, defined as research of no scientific importance and/or not meeting societal needs. We argue that this redundancy in research may to a large degree be due to the lack of a systematic evaluation of the best available evidence and/or of studies assessing societal needs. Objectives: The aim of this scoping review is to (A) identify meta-research studies evaluating if redundancy is present within biomedical research, and if so, assessing the prevalence of such redundancy, and (B) to identify meta-research studies evaluating if researchers had been trying to minimise or avoid redundancy. Eligibility criteria: Meta-research studies (empirical studies) were eligible if they evaluated whether redundancy was present and to what degree; whether health researchers referred to all earlier similar studies when justifying and designing a new study and/or when placing new results in the context of earlier similar trials; and whether health researchers systematically and transparently considered end users’ perspectives when justifying and designing a new study. Sources of evidence: The initial overall search was conducted in MEDLINE, Embase via Ovid, CINAHL, Web of Science, Social Sciences Citation Index, Arts & Humanities Citation Index, and the Cochrane Methodology Register from inception to June 2015. A 2nd search included MEDLINE and Embase via Ovid and covered January 2015 to 26 May 2021. No publication date or language restrictions were applied. Charting methods: Charting methods included description of the included studies, bibliometric mapping, and presentation of possible research gaps in the identified meta-research. Results: We identified 69 meta-research studies. Thirty-four (49%) of these evaluated the prevalence of redundancy and 42 (61%) studies evaluated the prevalence of a systematic and transparent use of earlier similar studies when justifying and designing new studies, and/or when placing new results in context, with seven (10%) studies addressing both aspects. Only one (1%) study assessed if the perspectives of end users had been used to inform the justification and design of a new study. Among the included meta-research studies evaluating whether redundancy was present, only two of nine health domains (medical areas) and only two of 10 research topics (different methodological types) were represented. Similarly, among the included meta-research studies evaluating whether researchers had been trying to minimise or avoid redundancy, only one of nine health domains and only one of 10 research topics were represented. Conclusions that relate to the review questions and objectives: Even with 69 included meta-research studies, there was a lack of information for most health domains and research topics. However, as most included studies were evaluating across different domains, there is a clear indication of a high prevalence of redundancy and a low prevalence of trying to minimise or avoid redundancy. In addition, only one meta-research study evaluated whether the perspectives of end users were used to inform the justification and design of a new study. Systematic review registration: Protocol registered at Open Science Framework: https://osf.io/3rdua/ (15 June 2021).
- 15 November 2022
- Published by Springer Nature in Systematic Reviews
- Vol. 11 (1) , 1-15
Open AccessMeta-research evaluating redundancy and use of systematic reviews when planning new studies in health research: a scoping review
Background: Several studies have documented the production of wasteful research, defined as research of no scientific importance and/or not meeting societal needs. We argue that this redundancy in research may to a large degree be due to the lack of a systematic evaluation of the best available evidence and/or of studies assessing societal needs. Objectives: The aim of this scoping review is to (A) identify meta-research studies evaluating if redundancy is present within biomedical research, and if so, assessing the prevalence of such redundancy, and (B) to identify meta-research studies evaluating if researchers had been trying to minimise or avoid redundancy. Eligibility criteria: Meta-research studies (empirical studies) were eligible if they evaluated whether redundancy was present and to what degree; whether health researchers referred to all earlier similar studies when justifying and designing a new study and/or when placing new results in the context of earlier similar trials; and whether health researchers systematically and transparently considered end users’ perspectives when justifying and designing a new study. Sources of evidence: The initial overall search was conducted in MEDLINE, Embase via Ovid, CINAHL, Web of Science, Social Sciences Citation Index, Arts & Humanities Citation Index, and the Cochrane Methodology Register from inception to June 2015. A 2nd search included MEDLINE and Embase via Ovid and covered January 2015 to 26 May 2021. No publication date or language restrictions were applied. Charting methods: Charting methods included description of the included studies, bibliometric mapping, and presentation of possible research gaps in the identified meta-research. Results: We identified 69 meta-research studies. Thirty-four (49%) of these evaluated the prevalence of redundancy and 42 (61%) studies evaluated the prevalence of a systematic and transparent use of earlier similar studies when justifying and designing new studies, and/or when placing new results in context, with seven (10%) studies addressing both aspects. Only one (1%) study assessed if the perspectives of end users had been used to inform the justification and design of a new study. Among the included meta-research studies evaluating whether redundancy was present, only two of nine health domains (medical areas) and only two of 10 research topics (different methodological types) were represented. Similarly, among the included meta-research studies evaluating whether researchers had been trying to minimise or avoid redundancy, only one of nine health domains and only one of 10 research topics were represented. Conclusions that relate to the review questions and objectives: Even with 69 included meta-research studies, there was a lack of information for most health domains and research topics. However, as most included studies were evaluating across different domains, there is a clear indication of a high prevalence of redundancy and a low prevalence of trying to minimise or avoid redundancy. In addition, only one meta-research study evaluated whether the perspectives of end users were used to inform the justification and design of a new study. Systematic review registration: Protocol registered at Open Science Framework: https://osf.io/3rdua/ (15 June 2021).
- Open Access
- 14 February 2021
- Published by Springer Nature in Scientometrics
- Vol. 126 (4) , 3303-3320
Quantitative quality: a study on how performance-based measures may change the publication patterns of Danish researchers
Nations the world over are increasingly turning to quantitative performance-based metrics to evaluate the quality of research outputs, as these metrics are abundant and provide an easy measure of ranking research. In 2010, the Danish Ministry of Science and Higher Education followed this trend and began portioning out a percentage of the available research funding according to how many research outputs each Danish university produces. Not all research outputs are eligible: only those published in a curated list of academic journals and publishers, the so-called BFI list, are included. The BFI list is ranked, which may create incentives for academic authors to target certain publication outlets or publication types over others. In this study we examine the potential effect these relatively new research evaluation methods have had on the publication patterns of researchers in Denmark. The study finds that publication behaviors in the Natural Sciences & Technology, Social Sciences and Humanities (SSH) have changed, while the Health Sciences appear unaffected. Researchers in Natural Sciences & Technology appear to focus on high impact journals that reap more BFI points. While researchers in SSH have also increased their focus on the impact of the publication outlet, they also appear to have altered their preferred publication types, publishing more journal articles in the Social Sciences and more anthologies in the Humanities.
- 14 February 2021
- Published by Springer Nature in Scientometrics
- Vol. 126 (4) , 3303-3320
Open AccessQuantitative quality: a study on how performance-based measures may change the publication patterns of Danish researchers
Nations the world over are increasingly turning to quantitative performance-based metrics to evaluate the quality of research outputs, as these metrics are abundant and provide an easy measure of ranking research. In 2010, the Danish Ministry of Science and Higher Education followed this trend and began portioning out a percentage of the available research funding according to how many research outputs each Danish university produces. Not all research outputs are eligible: only those published in a curated list of academic journals and publishers, the so-called BFI list, are included. The BFI list is ranked, which may create incentives for academic authors to target certain publication outlets or publication types over others. In this study we examine the potential effect these relatively new research evaluation methods have had on the publication patterns of researchers in Denmark. The study finds that publication behaviors in the Natural Sciences & Technology, Social Sciences and Humanities (SSH) have changed, while the Health Sciences appear unaffected. Researchers in Natural Sciences & Technology appear to focus on high impact journals that reap more BFI points. While researchers in SSH have also increased their focus on the impact of the publication outlet, they also appear to have altered their preferred publication types, publishing more journal articles in the Social Sciences and more anthologies in the Humanities.
- 1 October 2020
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 24 (51) , 1-220
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery. Established management largely involves platelet transfusion prior to the procedure or as rescue therapy for bleeding due to the procedure.Objectives: To assess the clinical effectiveness and cost-effectiveness of two thrombopoietin receptor agonists, avatrombopag (Doptelet®; Dova Pharmaceuticals, Durham, NC, USA) and lusutrombopag (Mulpleta®; Shionogi Inc., London, UK), in addition to established clinical management compared with established clinical management (no thrombopoietin receptor agonist) in the licensed populations.Design: Systematic review and cost-effectiveness analysis.Setting: Secondary care.Participants: Severe thrombocytopenia (platelet count of < 50,000/µl) in people with chronic liver disease requiring surgery.Interventions: Lusutrombopag 3 mg and avatrombopag (60 mg if the baseline platelet count is < 40,000/µl and 40 mg if it is 40,000–< 50,000/µl).Main outcome measures: Risk of platelet transfusion and rescue therapy or risk of rescue therapy only.Review methods: Systematic review including meta-analysis. English-language and non-English-language articles were obtained from several databases including MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials, all searched from inception to 29 May 2019.Economic evaluation: Model-based cost-effectiveness analysis.Results: From a comprehensive search retrieving 11,305 records, six studies were included. Analysis showed that avatrombopag and lusutrombopag were superior to no thrombopoietin receptor agonist in avoiding both platelet transfusion and rescue therapy or rescue therapy only, and mostly with a statistically significant difference (i.e. 95% confidence intervals not overlapping the point of no difference). However, only avatrombopag seemed to be superior to no thrombopoietin receptor agonist in reducing the risk of rescue therapy, although far fewer patients in the lusutrombopag trials than in the avatrombopag trials received rescue therapy. When assessing the cost-effectiveness of lusutrombopag and avatrombopag, it was found that, despite the success of these in avoiding platelet transfusions prior to surgery, the additional long-term gain in quality-adjusted life-years was very small. No thrombopoietin receptor agonist was clearly cheaper than both lusutrombopag and avatrombopag, as the cost savings from avoiding platelet transfusions were more than offset by the drug cost. The probabilistic sensitivity analysis showed that, for all thresholds below £100,000, no thrombopoietin receptor agonist had 100% probability of being cost-effective.Limitations: Some of the rescue therapy data for lusutrombopag were not available. There were inconsistencies in the avatrombopag data. From the cost-effectiveness point of view, there were several additional important gaps in the evidence required, including the lack of a price for avatrombopag.Conclusions: Avatrombopag and lusutrombopag were superior to no thrombopoietin receptor agonist in avoiding both platelet transfusion and rescue therapy, but they were not cost-effective given the lack of benefit and increase in cost.Future work: A head-to-head trial is warranted.Study registration: This study is registered as PROSPERO CRD42019125311.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 24, No. 51. See the NIHR Journals Library website for further project information.
- 1 October 2020
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 24 (51) , 1-220
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery. Established management largely involves platelet transfusion prior to the procedure or as rescue therapy for bleeding due to the procedure.Objectives: To assess the clinical effectiveness and cost-effectiveness of two thrombopoietin receptor agonists, avatrombopag (Doptelet®; Dova Pharmaceuticals, Durham, NC, USA) and lusutrombopag (Mulpleta®; Shionogi Inc., London, UK), in addition to established clinical management compared with established clinical management (no thrombopoietin receptor agonist) in the licensed populations.Design: Systematic review and cost-effectiveness analysis.Setting: Secondary care.Participants: Severe thrombocytopenia (platelet count of < 50,000/µl) in people with chronic liver disease requiring surgery.Interventions: Lusutrombopag 3 mg and avatrombopag (60 mg if the baseline platelet count is < 40,000/µl and 40 mg if it is 40,000–< 50,000/µl).Main outcome measures: Risk of platelet transfusion and rescue therapy or risk of rescue therapy only.Review methods: Systematic review including meta-analysis. English-language and non-English-language articles were obtained from several databases including MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials, all searched from inception to 29 May 2019.Economic evaluation: Model-based cost-effectiveness analysis.Results: From a comprehensive search retrieving 11,305 records, six studies were included. Analysis showed that avatrombopag and lusutrombopag were superior to no thrombopoietin receptor agonist in avoiding both platelet transfusion and rescue therapy or rescue therapy only, and mostly with a statistically significant difference (i.e. 95% confidence intervals not overlapping the point of no difference). However, only avatrombopag seemed to be superior to no thrombopoietin receptor agonist in reducing the risk of rescue therapy, although far fewer patients in the lusutrombopag trials than in the avatrombopag trials received rescue therapy. When assessing the cost-effectiveness of lusutrombopag and avatrombopag, it was found that, despite the success of these in avoiding platelet transfusions prior to surgery, the additional long-term gain in quality-adjusted life-years was very small. No thrombopoietin receptor agonist was clearly cheaper than both lusutrombopag and avatrombopag, as the cost savings from avoiding platelet transfusions were more than offset by the drug cost. The probabilistic sensitivity analysis showed that, for all thresholds below £100,000, no thrombopoietin receptor agonist had 100% probability of being cost-effective.Limitations: Some of the rescue therapy data for lusutrombopag were not available. There were inconsistencies in the avatrombopag data. From the cost-effectiveness point of view, there were several additional important gaps in the evidence required, including the lack of a price for avatrombopag.Conclusions: Avatrombopag and lusutrombopag were superior to no thrombopoietin receptor agonist in avoiding both platelet transfusion and rescue therapy, but they were not cost-effective given the lack of benefit and increase in cost.Future work: A head-to-head trial is warranted.Study registration: This study is registered as PROSPERO CRD42019125311.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 24, No. 51. See the NIHR Journals Library website for further project information.
- Open Access
- 1 December 2018
- Published by Ligue des Bibliotheques Europeennes de Recherche in LIBER Quarterly
- Vol. 28 (1)
Being a Deliberate Prey of a Predator – Researchers’ Thoughts after having Published in a Predatory Journal
- 1 December 2018
- Published by Ligue des Bibliotheques Europeennes de Recherche in LIBER Quarterly
- Vol. 28 (1)
Open AccessBeing a Deliberate Prey of a Predator – Researchers’ Thoughts after having Published in a Predatory Journal
- Open Access
- 1 August 2016
- Published by Ligue des Bibliotheques Europeennes de Recherche in LIBER Quarterly
- Vol. 26 (2) , 67-82
Sharing Data Increases Citations
This paper presents some indications to the existence of a citation advantage related to sharing data using astrophysics as a case. Through bibliometric analyses we find a citation advantage for astrophysical papers in core journals. The advantage arises as indexed papers are associated with data Liber Quarterly Volume 26 Issue 2 2016 by bibliographical links, and consists of papers receiving on average significantly more citations per paper per year, than do papers not associated with links to data.
- 1 August 2016
- Published by Ligue des Bibliotheques Europeennes de Recherche in LIBER Quarterly
- Vol. 26 (2) , 67-82
Open AccessSharing Data Increases Citations
This paper presents some indications to the existence of a citation advantage related to sharing data using astrophysics as a case. Through bibliometric analyses we find a citation advantage for astrophysical papers in core journals. The advantage arises as indexed papers are associated with data Liber Quarterly Volume 26 Issue 2 2016 by bibliographical links, and consists of papers receiving on average significantly more citations per paper per year, than do papers not associated with links to data.
- Open Access
- 1 August 2015
- Published by Cambridge University Press (CUP) in Proceedings of the International Astronomical Union
- Vol. 11 (A29A) , 172-175
The data sharing advantage in astrophysics
We present here evidence for the existence of a citation advantage within astrophysics for papers that link to data. Using simple measures based on publication data from NASA Astrophysics Data System we find a citation advantage for papers with links to data receiving on the average significantly more citations per paper than papers without links to data. Furthermore, using INSPEC and Web of Science databases we investigate whether either papers of an experimental or theoretical nature display different citation behavior.
- 1 August 2015
- Published by Cambridge University Press (CUP) in Proceedings of the International Astronomical Union
- Vol. 11 (A29A) , 172-175
Open AccessThe data sharing advantage in astrophysics
We present here evidence for the existence of a citation advantage within astrophysics for papers that link to data. Using simple measures based on publication data from NASA Astrophysics Data System we find a citation advantage for papers with links to data receiving on the average significantly more citations per paper than papers without links to data. Furthermore, using INSPEC and Web of Science databases we investigate whether either papers of an experimental or theoretical nature display different citation behavior.